Zentalis Pharmaceuticals (ZNTL) Equity Average (2019 - 2026)

Zentalis Pharmaceuticals' Equity Average history runs 8 years deep, the most recent figure standing at $199.4 million for Q1 2026.

• In Q1 2026, Equity Average fell 36.94% year-over-year to $199.4 million; the TTM figure through Mar 2026 stood at $199.4 million (down 36.94% YoY), while the FY2025 annual figure was $276.7 million, down 28.55% from the prior year.
• Equity Average was $199.4 million for Q1 2026 at Zentalis Pharmaceuticals, down from $234.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $502.6 million in Q3 2023 to a low of $199.4 million in Q1 2026.
• Historically, Equity Average has averaged $372.0 million across 5 years, with a median of $394.2 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Equity Average soared 45.95% in 2022, then plunged 36.94% in 2026.
• A 5-year view of Equity Average shows it stood at $431.4 million in 2022, then increased by 6.54% to $459.6 million in 2023, then declined by 24.77% to $345.8 million in 2024, then sank by 32.17% to $234.5 million in 2025, then declined by 14.96% to $199.4 million in 2026.
• The last three Equity Average figures came in at $199.4 million (Q1 2026), $234.5 million (Q4 2025), and $263.7 million (Q3 2025), per Business Quant data.